A pre-specified analysis of the DAPA-CKD trial

dapa totoDapagliflozin snificantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes.Dapagliflozin reduced the risk of kidney failure and prolonged survival in participants with chronic kidney disease with and without type 2 diabetes, including